Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress
- 8 June 2010
- journal article
- review article
- Published by Taylor & Francis Ltd in Nanomedicine
- Vol. 5 (4), 597-615
- https://doi.org/10.2217/nnm.10.35
Abstract
Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. P-glycoprotein is an important and the best-known membrane transporter involved in MDR. Several strategies have been used to address MDR, especially P-glycoprotein-mediated drug resistance in tumors. However, clinical success has been limited, largely due to issues regarding lack of efficacy and/or safety. Nanoparticles have shown the ability to target tumors based on their unique physical and biological properties. To date, nanoparticles have been investigated primarily to address P-glycoprotein and the observed improved anticancer efficacy suggests that nanomedicinal strategies provide a new opportunity to overcome MDR. This article focuses on nanotechnology-based formulations and current nanomedicine approaches to address MDR in tumors and discusses the proposed mechanisms of action.This publication has 166 references indexed in Scilit:
- Differential metabolic responses to pluronic in MDR and non-MDR cells: A novel pathway for chemosensitization of drug resistant cancersJournal of Controlled Release, 2010
- The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistanceBiomaterials, 2010
- Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiersJournal of Controlled Release, 2008
- An orally delivered small-molecule formulation with antiangiogenic and anticancer activityNature Biotechnology, 2008
- Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalizationMicrovascular Research, 2007
- Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer CellsBiochemical and Biophysical Research Communications, 2001
- Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cellsEuropean Journal of Cancer, 1995
- Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.JCI Insight, 1995
- Multidrug resistance and the role of P-glycoprotein knockout miceEuropean Journal of Cancer, 1995
- Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in cultureEuropean Journal of Cancer, 1994